Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CESAR: Esketamine vs Aripiprazole in Elderly TR-MDD
NCT07153406Phase 3Not yet recruiting
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esketamine in major depressive disorder (MDD), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07153406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153406.